A share price of United Therapeutics Corp [UTHR] is currently trading at $308.00, up 0.35%. An important factor to consider is whether the stock is rising or falling in short-term value. The UTHR shares have gain 4.82% over the last week, with a monthly amount glided 10.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
United Therapeutics Corp [NASDAQ: UTHR] stock has seen the most recent analyst activity on April 25, 2025, when Wells Fargo downgraded its rating to a Equal Weight. Previously, BofA Securities upgraded its rating to Neutral on April 21, 2025, and kept the price target unchanged to $314. On July 11, 2024, downgrade downgraded it’s rating to Equal-Weight and revised its price target to $321 on the stock. Goldman upgraded its rating to a Neutral and increased its price target to $215 on February 12, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $330 as its price target on February 05, 2024. Wells Fargo started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $309. In a note dated December 06, 2022, UBS initiated an Buy rating and provided a target price of $320 on this stock.
United Therapeutics Corp experienced fluctuations in its stock price throughout the past year between $260.41 and $417.82. Currently, Wall Street analysts expect the stock to reach $314 within the next 12 months. United Therapeutics Corp [NASDAQ: UTHR] shares were valued at $308.00 at the most recent close of the market. An investor can expect a potential return of 1.95% based on the average UTHR price forecast.
Analyzing the UTHR fundamentals
Trailing Twelve Months sales for United Therapeutics Corp [NASDAQ:UTHR] were 2.99B which represents 17.22% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.47%, Pretax Profit Margin comes in at 0.52%, and Net Profit Margin reading is 0.4%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.19 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 301.17 points at the first support level, and at 294.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 313.02, and for the 2nd resistance point, it is at 318.05.
Ratios To Look Out For
To put it in perspective, the Current Ratio for United Therapeutics Corp [NASDAQ:UTHR] is 5.46. On the other hand, the Quick Ratio is 5.23, and the Cash Ratio is 2.63. Considering the valuation of this stock, the price to sales ratio is 4.64, the price to book ratio is 2.04 and price to earnings (TTM) ratio is 12.29.
Transactions by insiders
Recent insider trading involved MAHON PAUL A, EVP & GENERAL COUNSEL, that happened on May 01 ’25 when 11000.0 shares were sold. Officer, PAUL MAHON completed a deal on May 01 ’25 to buy 11000.0 shares. Meanwhile, Director DWEK RAYMOND sold 3000.0 shares on Apr 21 ’25.
